4 most recent filings and news items mentioning VYNE. Updated every 60 seconds.
M&AJul 21, 2026Neutral
Vyne Therapeutics Inc. announced a 1-for-50 reverse stock split and a special cash dividend of $17.3 million ahead of its pending merger with Yarrow Bioscience, facilitating the combined company's transition to the ticker YARW.
View filing at SEC.gov →
M&AJul 14, 2026Neutral
VYNE Therapeutics filed Exhibit 99.1 detailing a proposed reverse merger with Yarrow Bioscience and concurrent financing. This corporate restructuring could provide VYNE's preclinical programs with necessary capital and strategic oversight.
View filing at SEC.gov →
DividendJul 10, 2026Positive
VYNE Therapeutics Inc. announced a special cash dividend of approximately $16.5 million, or $0.38 per share, linked to its pending acquisition by Yarrow Bioscience. The distribution is contingent on the successful completion of the transaction.
View filing at SEC.gov →
M&AMay 21, 2026Neutral
VYNE Therapeutics filed an exhibit containing a Yarrow Bioscience company overview presentation dated May 2026, indicating preparation for a proposed reverse merger transaction with concurrent financing. The filing suggests potential corporate restructuring activity that could ma
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.